Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Express Scripts
Harvard Business School
Deloitte
Dow
Baxter
Julphar
McKesson
Cerilliant

Generated: April 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,348,361

« Back to Dashboard

Which drugs does patent 7,348,361 protect, and when does it expire?

Patent 7,348,361 protects CYSVIEW KIT and is included in one NDA.

This patent has ten patent family members in eight countries.
Summary for Patent: 7,348,361
Title:Solution for diagnosing or treating tissue pathologies
Abstract:The invention concerns a 5-aminolevulinic acid ester (E-ALA) solution for producing a pharmaceutical preparation useful for diagnosing and/or treating tissue and/or cell pathologies by local radiation exposure using radiation emitted by a light source energy followed, in the case diagnosis, by detection of fluorescent protoporphyrin IX (Pp1X). The E-ALA concentration in the solution is less than 1% and ranges between 0.01% and 0.5%. The low E-ALA concentration in the solution increases Pp1X synthesis and homogenises its distribution in the cell layers while highly reducing the secondary toxicity for the treated cells.
Inventor(s): Marti; Alexandre (Geneva, CH), Lange; Norbert (Lausanne, CH), Zellweger; Matthieu (Lausanne, CH), Wagnieres; Georges (Morges, CH), Van Den Bergh; Hubert (Goumoens-la-Ville, CH), Jichlinski; Patrice (Le Mont-sur-Lausanne, CH), Kucera; Pavel (Lausanne, CH)
Assignee: Ecole Polytechnique Federale de Lausanne (Lausanne, CH)
Application Number:09/673,871
Patent Claim Types:
see list of patent claims
Use; Composition; Compound; Formulation;

Drugs Protected by US Patent 7,348,361

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Photocure Asa CYSVIEW KIT hexaminolevulinate hydrochloride FOR SOLUTION;INTRAVESICAL 022555-001 May 28, 2010 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Photocure Asa CYSVIEW KIT hexaminolevulinate hydrochloride FOR SOLUTION;INTRAVESICAL 022555-001 May 28, 2010 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y DETECTION OF NON-MUSCLE INVASIVE PAPILLARY CANCER OF THE BLADDER BY PHOTODYNAMIC CYSTOSCOPY ➤ Try a Free Trial
Photocure Asa CYSVIEW KIT hexaminolevulinate hydrochloride FOR SOLUTION;INTRAVESICAL 022555-001 May 28, 2010 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y DETECTION OF NON-MUSCLE INVASIVE PAPILLARY CANCER OF THE BLADDER BY PHOTODYNAMIC CYSTOSCOPY ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,348,361

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France98 05425Apr 22, 1998
PCT Information
PCT FiledApril 22, 1999PCT Application Number:PCT/CH99/00163
PCT Publication Date:October 28, 1999PCT Publication Number: WO99/53962

International Patents Family Members for US Patent 7,348,361

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Germany 69904033 ➤ Try a Free Trial
European Patent Office 1073472 ➤ Try a Free Trial
Spain 2188146 ➤ Try a Free Trial
France 2777782 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Cipla
Boehringer Ingelheim
Mallinckrodt
UBS
Farmers Insurance
Fuji
Moodys
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.